UNSPSC 51171940: Fenoctimine

This classification denotes an anti-ulcer agent with the molecular formula C27H38N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, B45CF873F8 chemically known as 4-(diphenylmethyl)-1-(n-octylformimidoyl)piperidine, hemihydrate but generally known as fenoctimine, which bears US NIH Compound Identifier 50455. European Medicines Agency schedules Fenoctimine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07575MIG.

UNSPSC 51171940 Fenoctimine (Commodity) names a pharmaceutical product that state and local governments procure primarily through two distinct channels: direct procurement for offender drug testing and screening programs, and participation in cooperative purchasing agreements for multi-state pharmaceutical distribution. Recent solicitations show this code captures both specimen-collection-and-testing services where fenoctimine or similar immunoassay screening agents may be deployed, and broader generic pharmaceutical supply contracts through cooperative vehicles. State and local issuing bodies under this code include county criminal-justice agencies (community supervision and corrections departments), state health and human services commissions, and cooperative purchasing alliances serving multi-state networks of state facilities and participating local jurisdictions. Collin County Community Supervision and Corrections Department's July 2026 RFP for offender specimen collection and drug testing services represents the most direct match: the solicitation covers immunoassay screening with confirmation testing across two collection sites in Plano and McKinney, with approximately 25,031 tests annually across five-panel and six-panel screening protocols, an estimated contract value of $600,000, and a two-year initial term with three optional one-year renewal periods commencing September 1, 2026.

The code sees activity across Texas and multi-state cooperative purchasing zones. Texas Health and Human Services Commission issued an RFI in April 2026 on therapeutic pharmacy initiatives and direct-to-manufacturer prescriptions, signaling emerging state-level interest in alternative pharmacy benefit contracting models that could affect commodity-level pharmaceutical procurement structure. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration and serving participating jurisdictions including Oregon, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline; this cooperative vehicle establishes multi-award contracts effective July 1, 2026, distributed through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson), with evaluation weighted 75 percent on price competitiveness and 25 percent on compliance, EDI capability, and administrative fees. Recent activity suggests the code attracts both specialized offender-testing procurement and broad pharmaceutical distribution through cooperative purchasing, with Texas and multi-state zones as the primary active jurisdictions.